Application of Third-Generation (3G) Mobile Videophone to the DOTS-Plus Program in Multidrug-Resistant Tuberculosis in Taiwan: Case Report

鄧 穎佳(Veng-Kai Tang), 白 冠壬(Kuan-Jen Bai), 王 錦雲(Chin-Yun Wang), 余 明治(Ming-Chih Yu)

Research output: Contribution to journalArticle

Abstract

Multidrug-resistant tuberculosis (MDR-TB), caused by the bacterium, Mycobacterium tuberculosis, is resistant to both isoniazid and rifampicin and is a phenomenon threatening to destabilize global tuberculosis control. Taiwan's Centers for Disease Control implemented a patient-centered DOTS (directly observed treatment, short-course)-Plus program for MDR-TB patients in May 2007. We report the case of a 71-year-old MDR-TB patient who successfully completed 18 months of MDR-TB treatment under the DOTS-Plus program, beginning October 2007. A third-generation (3G) mobile videophone was used to watch the patient take medicine throughout his course of treatment. His acceptance of the program and compliance with monitoring by videophone DOT (V-DOT) were excellent. We conclude that V-DOT can be an effective approach to case management for MDR-TB patients and can achieve a high level of adherence in selected cooperative cases in Taiwan.
Original languageEnglish
Pages (from-to)7-12
Number of pages6
Journal胸腔醫學
Volume25
Issue number1
Publication statusPublished - 2010

Fingerprint

Multidrug-Resistant Tuberculosis
Taiwan
Therapeutics
Isoniazid
Case Management
Rifampin
Centers for Disease Control and Prevention (U.S.)
Mycobacterium tuberculosis
Tuberculosis
Medicine
Bacteria

Keywords

  • 多重抗藥結核病
  • 進階都治計畫
  • 3G影像手機
  • multidrug-resistant tuberculosis
  • DOTS-Plus
  • 3G mobile videophone

Cite this

Application of Third-Generation (3G) Mobile Videophone to the DOTS-Plus Program in Multidrug-Resistant Tuberculosis in Taiwan: Case Report. / 鄧穎佳(Veng-Kai Tang); 白冠壬(Kuan-Jen Bai); 王錦雲(Chin-Yun Wang); 余明治(Ming-Chih Yu).

In: 胸腔醫學, Vol. 25, No. 1, 2010, p. 7-12.

Research output: Contribution to journalArticle

@article{8c49b909273f4d9f962760e0a08ba575,
title = "Application of Third-Generation (3G) Mobile Videophone to the DOTS-Plus Program in Multidrug-Resistant Tuberculosis in Taiwan: Case Report",
abstract = "Multidrug-resistant tuberculosis (MDR-TB), caused by the bacterium, Mycobacterium tuberculosis, is resistant to both isoniazid and rifampicin and is a phenomenon threatening to destabilize global tuberculosis control. Taiwan's Centers for Disease Control implemented a patient-centered DOTS (directly observed treatment, short-course)-Plus program for MDR-TB patients in May 2007. We report the case of a 71-year-old MDR-TB patient who successfully completed 18 months of MDR-TB treatment under the DOTS-Plus program, beginning October 2007. A third-generation (3G) mobile videophone was used to watch the patient take medicine throughout his course of treatment. His acceptance of the program and compliance with monitoring by videophone DOT (V-DOT) were excellent. We conclude that V-DOT can be an effective approach to case management for MDR-TB patients and can achieve a high level of adherence in selected cooperative cases in Taiwan.",
keywords = "多重抗藥結核病, 進階都治計畫, 3G影像手機, multidrug-resistant tuberculosis, DOTS-Plus, 3G mobile videophone, 多重抗藥結核病, 進階都治計畫, 3G影像手機, multidrug-resistant tuberculosis, DOTS-Plus, 3G mobile videophone",
author = "鄧, {穎佳(Veng-Kai Tang)} and 白, {冠壬(Kuan-Jen Bai)} and 王, {錦雲(Chin-Yun Wang)} and 余, {明治(Ming-Chih Yu)}",
year = "2010",
language = "English",
volume = "25",
pages = "7--12",
journal = "胸腔醫學",
issn = "1023-9855",
publisher = "臺灣胸腔暨重症加護醫學會",
number = "1",

}

TY - JOUR

T1 - Application of Third-Generation (3G) Mobile Videophone to the DOTS-Plus Program in Multidrug-Resistant Tuberculosis in Taiwan: Case Report

AU - 鄧, 穎佳(Veng-Kai Tang)

AU - 白, 冠壬(Kuan-Jen Bai)

AU - 王, 錦雲(Chin-Yun Wang)

AU - 余, 明治(Ming-Chih Yu)

PY - 2010

Y1 - 2010

N2 - Multidrug-resistant tuberculosis (MDR-TB), caused by the bacterium, Mycobacterium tuberculosis, is resistant to both isoniazid and rifampicin and is a phenomenon threatening to destabilize global tuberculosis control. Taiwan's Centers for Disease Control implemented a patient-centered DOTS (directly observed treatment, short-course)-Plus program for MDR-TB patients in May 2007. We report the case of a 71-year-old MDR-TB patient who successfully completed 18 months of MDR-TB treatment under the DOTS-Plus program, beginning October 2007. A third-generation (3G) mobile videophone was used to watch the patient take medicine throughout his course of treatment. His acceptance of the program and compliance with monitoring by videophone DOT (V-DOT) were excellent. We conclude that V-DOT can be an effective approach to case management for MDR-TB patients and can achieve a high level of adherence in selected cooperative cases in Taiwan.

AB - Multidrug-resistant tuberculosis (MDR-TB), caused by the bacterium, Mycobacterium tuberculosis, is resistant to both isoniazid and rifampicin and is a phenomenon threatening to destabilize global tuberculosis control. Taiwan's Centers for Disease Control implemented a patient-centered DOTS (directly observed treatment, short-course)-Plus program for MDR-TB patients in May 2007. We report the case of a 71-year-old MDR-TB patient who successfully completed 18 months of MDR-TB treatment under the DOTS-Plus program, beginning October 2007. A third-generation (3G) mobile videophone was used to watch the patient take medicine throughout his course of treatment. His acceptance of the program and compliance with monitoring by videophone DOT (V-DOT) were excellent. We conclude that V-DOT can be an effective approach to case management for MDR-TB patients and can achieve a high level of adherence in selected cooperative cases in Taiwan.

KW - 多重抗藥結核病

KW - 進階都治計畫

KW - 3G影像手機

KW - multidrug-resistant tuberculosis

KW - DOTS-Plus

KW - 3G mobile videophone

KW - 多重抗藥結核病

KW - 進階都治計畫

KW - 3G影像手機

KW - multidrug-resistant tuberculosis

KW - DOTS-Plus

KW - 3G mobile videophone

UR - http://www.tspccm.org.tw/media/916

M3 - Article

VL - 25

SP - 7

EP - 12

JO - 胸腔醫學

JF - 胸腔醫學

SN - 1023-9855

IS - 1

ER -